Hims & Hers adds Zepbound, Mounjaro, and liraglutide to platform

Hims & Hers Health shares closed up 5% on Tuesday after the corporate announced patients can access Eli Lilly‘s weight reduction medication Zepbound and diabetes drug Mounjaro, in addition to the generic injection liraglutide, through its platform.

Zepbound, Mounjaro and liraglutide are a part of the category of weight reduction medications called GLP-1s, which have exploded in popularity lately. Hims & Hers launched a weight reduction program in late 2023, but its GLP-1 offerings have evolved as the corporate has contended with a volatile supply and regulatory environment.

Lilly’s weekly injections Zepbound and Mounjaro will cost patients $1,899 a month, in response to the Hims & Hers website. The generic liraglutide will cost $299 a month, but it surely requires a each day injection and could be less effective than other GLP-1 medications.

“As we glance ahead, we plan to proceed to expand our weight reduction offering to deliver an excellent more holistic, personalized experience,” Dr. Craig Primack, senior vp of weight reduction at Hims & Hers, wrote in a blog post.

A Lilly spokesperson said in an announcement that the corporate has “no affiliation” with Hims & Hers and noted that Zepbound is out there at lower costs for people who find themselves insured for the product or for many who buy directly from the corporate. 

In May, Hims & Hers began prescribing compounded semaglutide, the energetic ingredient in Novo Nordisk’s GLP-1 weight reduction medications Ozempic and Wegovy. The offering was immensely popular and helped generate greater than $225 million in revenue for the corporate in 2024.

But compounded drugs can traditionally only be mass produced when the branded medications treatments are in shortage. The U.S. Food and Drug Administration announced in February that the shortage of semaglutide injections products had been resolved.

That meant Hims & Hers needed to largely stop offering the compounded medications, though some consumers should give you the chance to access personalized doses if it’s clinically applicable. 

Through the company’s quarterly call with investors in February, Hims & Hers said its weight reduction offerings will primarily consist of its oral medications and liraglutide. The corporate said it expects its weight reduction offerings to generate not less than $725 million in annual revenue, excluding contributions from compounded semaglutide.

But the corporate remains to be lobbying for compounded medications. A pop up on Hims & Hers’ website, which was viewed by CNBC, encourages users to “use your voice” and urge Congress and the FDA to preserve access to compounded treatments.

With Tuesday’s rally, Hims and Hers shares are up about 27% in 2025 after soaring 172% last 12 months.

WATCH: Hims & Hers shares tumble over concerns around weight-loss business